Principal Investigator/Program Director:
Meyskens, Frank L.
BIOGRAPHICAL SKETCH
5P30CA062203-17
NAME
POSITION TITLE
Tewari, Krishnansu S.
Associate Clinical Professor
eRA COMMONS USER NAME (credential, e.g., agency login)
KTEWARI
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION
University of California, Berkeley, Berkeley, CA
University of California, Irvine, Irvine, CA
University of California, Irvine, Irvine, CA
University of California, Irvine, Irvine, CA
DEGREE
(if applicable)
B.S.
M.D.
Residency
Fellowship
YEAR(s)
06/90
06/94
06/98
06/02
FIELD OF STUDY
Medicine
Obstetrics & Gynecology
Gynecologic Oncology
A. Personal Statement
I have experience in clinical trial design and execution as the principal investigator of many clinical trials
including: 1. the first phase III randomized clinical trial of anti-angiogenesis therapy and non-platinum
chemotherapy doublets in cervical cancer, which is open throughout the United States and in Europe; 2. the
Gynecologic Oncology Group (GOG) at UC Irvine, which oversees the activation and accrual of GOG trials at
UCI and the 12 other UCI GOG Affiliate medical centers; 3. The study of robotic surgery in cervical cancer, the
prospective study of robotic radical hysterectomy versus open radical hysterectomy for early stage carcinoma
of the cervix. In addition to these clinical trials, I am a full member of the Cervix and Vulvar Medicine
Committee of the Gynecologic Oncology Group and the co-Chair of the Clinical Trials Protocol Review and
Monitoring Committee at UCI’s Chao Family NCI-Designated Comprehensive Cancer Center. I have
successfully completed contracted research with industry for a large number of phase II trials in ovarian cancer
including, Amgen, Precision Therapeutics, Biogen Idec, Johnson & Johnson, Genentech, Imclone.
I also have experience in Translational Research through the study of surrogate markers of angiogenesis
and ERCC1/BRCA1 excision repair in cervical cancer: We looked at novel biologic markers of treatment
resistance in locally advanced cervical carcinoma. I am also a full Member of the Committee of Experimental
Medicine of the Gynecologic Oncology Group. Recently, I was appointed the Director of the Women's Disease
Oriented Team with Lydia Su at UCI’s Chao Family NCI-Designated Comprehensive Cancer Center.
For many years, I have played an active role in Clinical Practice Performance. I have been a recognized
expert in robotic surgery in gynecologic oncology and have been invited by the Intuitive Surgical Scientific
Steering Committee to submit an application for research funding for robotic surgery in cervical cancer. I
oversee the opening and conduct of Ann’s Clinic at UC Irvine Medical Center which will serve as a high risk
clinic to evaluate women at potential/perceived/documented genetic/familial risk for ovarian and breast cancer.
I have been listed annually as one of the Top Doctors in Orange County by the OCMA and am also nationally
listed as one of the Best Doctors in America. In addition to these clinical roles, I am a member of the editorial
Board for The Female Patient magazine and Women & Cancer magazine.
In summary, through my extensive experience conducting clinical trial design, translational research and
clinical practice, and through my ongoing work in the Gynecologic Oncology Group (both as the PI and Study
Chair of a phase 3 randomized trial), I am extremely well-qualified to carry out the clinical and translational
aspects of the research proposed in this application.
B. Positions and Honors
Positions and Employment
1998-2002
Clinical Instructor, Department of Obstetrics and Gynecology, University of California, Irvine,
Irvine, CA
2002-2006
Volunteer Faculty, Department of Obstetrics and Gynecology, University of California, Irvine,
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Principal Investigator/Program Director:
2006
2008
Meyskens, Frank L.
5P30CA062203-17
Irvine, CA
Assistant Clinical Professor of Health Sciences, Department of Obstetrics and Gynecology,
Division of Gynecologic Oncology, University of California, Irvine, Irvine, CA
Associate Clinical Professor of Clinical X, Department of Obstetrics and Gynecology, Division of
Gynecologic Oncology, University of California, Irvine, Irvine, CA
Other Experience and Professional Memberships
2002-2006
Kaiser Permanente, Riverside, CA
2008Co-Principal Investigator, Gynecologic Oncology Group, UC Irvine
2008President, Orange County Ob/Gyn Society
2008Member, Committee on Experimental Medicine, GOG.
2007Member, American Society of Clinical Oncology
2006Member, American Society of Colposcopy & Cervical Pathology
2006Member, American College of Surgeons
2006Member, Society of Gynecologic Oncologists
2006Member, Western Association of Gynecologic Oncologists
2006Member, International Society of Gynecologic Cancer
2006-2008
Vice President, Orange County Ob/Gyn Society
2006
Secretary-Treasurer, Orange County Ob/Gyn Society
2005Member, Cervix and Vulvar Medicine Committee, GOG
2004Fellow, American College of Obstetrics & Gynecology
2002Member, Gynecologic Oncology Group (GOG)
2002-2006
Candidate, Society of Gynecologic Oncologists
1998Member, The Philip J. DiSaia MD Society
Honors
1983
1994
1994
1994
1994
2000
2000
2000
2003
2004
2005
2006
2007
2007
2007
2007
2008
2009
Alumni Scholar, UC Berkeley
Educational Affairs Service Award – UCI College of Medicine
Senior Humanitarian Award – Medical Students of UCI COM
Alfred H. Edwards, MD Memorial Scholarship Award UCI Medical Alumni
Association
Upjohn foundation Award for Academic Excellence
1st Prize Award, $5,000.00, International Gynecologic Cancer Society
Association of the Argentinian Knights of the Sovereign & Military Order of Malta
Philip J. DiSaia Society Resident Mentorship Award
American Radium Society Young Oncologist Award
Merit Award, Kaiser Permanente Medical Center, Baldwin Park, CA
Merit Award, Kaiser Permanente Medical Center, Baldwin Park, CA
Merit Award, Kaiser Permanente Medical Center, Baldwin Park, CA
John Molitor MD Volunteer Clinical Faculty Award - UCIMC
Nominated for ARISE Award – UC Irvine Medical Center
Abraxis Oncology/GOG Young Investigator Award - $25,000.00
Thomas J Garite, MD Faculty Teaching Award – UC Irvine
Dean’s Junior Physician Scientist Award – UC Irvine - $5,000.00
Orange Coast Magazine Physician of Excellence, Orange County Med Assoc
Orange Coast Magazine Physician of Excellence, Orange County Med Assoc
C. Selected Peer-reviewed Publications (Selected from 68 peer-reviewed publications)
Most relevant to the current application
1. Kalantari M, Chase DM, Tewari KS, Bernard H-U. Recombination of human papillomavirus-16 and host
DNA in exfoliated cervical cells: A pilot study of L1 gene methylation and chromosomal integration as
biomarkers of carcinogenic progression.. J Med Virology 2010;82:311-20. PMID 20029805.
PHS 398/2590 (Rev. 06/09)
Page
Biographical Sketch Format Page
Principal Investigator/Program Director:
Meyskens, Frank L.
5P30CA062203-17
2. Tewari KS, Mehta RS, Burger RA, Kyshtoobayeva AS, Yu I-R, Monk BJ, Manetta A, Berman ML, DiSaia
PJ and Fruehauf JP. Conservation of in vitro drug resistance patterns in epithelial ovarian cancer.
Gynecologic Oncology, 2005;98:360-8. PMID 16000215.
3. Tewari KS, Kyshtoobayeva AS, Mehta RS, Yu I-R, Burger RA, DiSaia PJ and Fruehauf JP. Biomarker
conservation in primary and metastatic epithelial ovarian cancer. Gynecol Oncol 2000;78:130-6. PMID
10926791.
4. Tewari KS, Taylor JA, Liao SY, DiSaia PJ, Burger RA, Monk BJ, Hughes CCW and Villarreal LP.
Development and assessement of a general theory of cervical carcinogenesis utilizing a severe combined
immunodeficiency murine-human xenograft model. Gynecol Oncol 2000;77:137-48. PMID 10739703.
5. Taylor JA, Tewari K, Liao SY, Hughes CCW and Villarreal LP. Immunohistochemical analysis, human
papillomavirus DNA detection, hormonal manipulation and exogenous gene expression of normal and
dysplastic human cervical epithelium in severe combined immunodeficiency mice. J Virol 1999;73:5144-8.
PMID 10233978. PMCID 112560.
Additional recent publications of importance to the field (in chronological order)
1. Tewari KS, Monk BJ. Gynecologic Oncology Group trials of chemotherapy for metastatic and recurrent
cervical carcinoma. Curr Oncol Rep, 2005;7:419-34. PMID 16221379.
2. Monk BJ, Tewari KS. The spectrum and clinical sequelae of human papillomavirus infection. Gynecol
Oncol 2007;107:S6-13. PMID 18499914
3. Monk BJ, Tewari KS, Koh W-J. Multimodality therapy for locally advanced cervical carcinoma: State of the
art and future directions. J Clin Oncol 2007; 25:2952-65. PMID 17617527
4. Tewari KS, Monk BJ. Recent achievements and future developments in advanced and recurrent cervical
cancer: Trials of the Gynecologic Oncology Group. Semin Oncol 2009;36:170-80. PMID 19332251
5. Tewari KS, Monk BJ. Beyond platinum for metastatic and recurrent carcinoma of the cervix. Onkologie
2009;32:552-4. PMID 19816070
6. Tewari KS. A critical need for reappraisal of therapeutic options for women with metastatic and recurrent
cervical carcinoma: Commentary on Gynecologic Oncology Group protocol 204. Am J Hematol Oncol
2010;9:31-4.
7. Tewari KS, Monk BJ. The rationale for the use of non-platinum chemotherapy doublets for metastatic and
recurrent cervical carcinoma. Clin Adv Hematol Oncol 2010;8:108-15. PMID 20386532
8. Tewari KS. Patients with metastatic/recurrent cervical cancer should be treated with cisplatin plus
paclitaxel. Expert Panel. Clin Ovarian Cancer (in press).
9. Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, Ivanov I, Tewari KS, Mannel RS,
Zanotti K, Benbrook DM. Randomized phase III trial of tamoxifen versus thalidomide in women with
biochemical-recurrent-only epithelial ovarian, fallopian tube, or primary peritoneal carcinoma after a
complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular
endothelial growth factor (VEGF): A Gynecologic Oncology Group study. Gynecol Oncol 2010;119:444-50.
PMID 20846715.
10. Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Miller CY, Warshal DP, McMeekin S,
Rotmensch J. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent
intermediately platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group
trial. Int J Gynecol Cancer 2010;20:1137-41. PMID 21495215. PMCID 3079178.
D. Research Support
Ongoing Research Support
Tewari KS (PI)
1/1/2012-12/31/2012
Intuitive Surgical, Inc.
Principal Investigator and Study Chair to study robotic surgery in cervical cancer Prospective study of robotic
radical hysterectomy versus open radical hysterectomy for early stage carcinoma of the cervix.
5P30CA062203-16
NIH/NCI
PHS 398/2590 (Rev. 06/09)
Meyskens (PI)
02/01/09-01/31/14
Page
Biographical Sketch Format Page
Principal Investigator/Program Director:
Meyskens, Frank L.
5P30CA062203-17
University of California Irvine Cancer Center Support Grant Infrastructure and Research award to support
cancer research at UC Irvine and beyond.
Role: Co-leader for the Cervix Translational Working Group
1CP1508020936-1 Tewari (PI)
04/30/10-04/29/13
ImcloneSys
UCI 09-36: Randomized Ph 2 Trial Investigating Liposomal Doxorubicin With or Without Anti-Platelet Derived
Growth Factor Receptor-Alpha (PDGRFa) Monoclonal Antibody IMC-3G3 in Patients with Platinum-Refractory
or Platinum-Resistant Advanced Ovarian Cancer.
The goal of study is to investigate the activity of doxorubicin with IMC-3G3 in ovarian cancer.
Role: PI
1PT301-1
Tewari (PI)
03/26/09-03/01/12
Precision Therapeutics Inc.
Clinical Trail
A non-interventional prospective study of the correlation of the Precision Therapeutics Inc. chemoresponse
assay with progression-free survival in patients with recurrent epithelial ovarian, peritoneal, or fallopian tube
cancer. UCI 08-08.
Role: PI
1CP120711-1
Tewari (PI)
01/30/09-12/01/13
ImcloneSys
Clinical Trial
UCI 08-07: Ph 2, Non-Randomized, Open-Label Multicenter Study of IMC-1121B in Persistent or Recurrent
Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Role: PI
1TXA1272007002-1 Tewari (PI)
09/15/08-09/14/13
USBio
Clinical Trial
UCI 08-06: Ph IIb TXA127 in Reduction of Thrombocytopenia in Recurrent Ovarian Carcinoma
Role: PI
1R21CA156032-1
Tewari (PI)
01/01/11-12/31/12
NIH-NCI
Novel Biologic Markers of Treatment Resistance in Locally Advanced Cervical Carcinomas
Role: PI
1SHH4489G-1
Tewari (PI)
03/12/09-10/10/12
Genentech
Clinical Trial
UCI 08-43: Phil GDC-0449 as Maintenance in Ovarian Cancer in 2nd or 3rd Complete Remission
Role: PI
2U102746946-23
Tewari (PI)
GOG
Gynecologic Oncology Group
Role: PI
07/01/89-03/31/16
Completed Research
1206OC201-2
Tewari (PI)
Biogen
Clinical Trail
PHS 398/2590 (Rev. 06/09)
01/28/08-01/27/10
Page
Biographical Sketch Format Page